CJC-1295 and sermorelin have different tests behind them
Do these drugs have equal proof of benefit? No: one lasts longer and the other once had child-treatment approval. Neither has proved that you will stay healthier as you age.
The main difference is the evidence for treatment
Does the same action mean the same proof of benefit? No: CJC-1295 and sermorelin have different treatment histories.
Both prompt the gland to release the body's growth hormone. The usual bursts can continue while hormone levels rise between bursts.
Sermorelin once treated children lacking growth hormone [10][11]. Its Category 1 listing now allows pharmacy preparation under temporary rules.
CJC-1295 was changed to slow breakdown, especially in the DAC form. Early blood-test rises didn't lead to an approved treatment [1][4].
Neither drug is a food supplement or a proved healthy-aging treatment. Your daily health needs more proof than a hormone rise.
The drugs differ in how long they last and pharmacy rules
| What matters to you | CJC-1295 | Sermorelin |
|---|---|---|
| What the drug copies | A changed piece of hormone. DAC also fastens to a protein that blood carries. | A shortened copy of natural hormone with 29 amino acids, tiny joined parts that form proteins. |
| Changes in hormone release | Growth hormone in bursts. DAC makes the action last longer. | Growth hormone in bursts. The body can still limit further release. |
| How soon blood clears the drug | With DAC, about half remains after 5.8-8.1 days [4]. No-DAC clears within hours. | The body clears the drug within minutes to a few hours. |
| Who researchers tested | Healthy adults, mainly measuring blood changes. Mice unable to make the usual hormone-release message. | Children short of growth hormone. An older-adult trial used tesamorelin, a related drug. |
| What happened in human tests | Hormone levels rose [4][5]. Lasting benefits and years of safety remain unproved. | Children grew faster [11]. Tesamorelin was used in the adult trial [8]; other papers gave medical opinions [9][10]. |
| What the pharmacy rules mean | Never approved. October 2024 advisers opposed allowing this drug onto the list of prescription ingredients [1]. | Once approved for children. Sales ended in 2008; Category 1 allows pharmacy preparation under temporary rules [10]. |
| What competitors face | WADA, the group setting drug rules for sport, bans use all year under Section S2 [2]. Tests can detect the drug. | Sport rules ban sermorelin and other drugs that prompt growth-hormone release. |
| What risks remain | The FDA worried about the immune system fighting the drug [1]. Growth proteins stay raised; Phase 2 treatment tests stopped before approval. Form names get confused [4][7]. | Aging benefits are unproved [9]. Years of adult safety are unknown; continuous supply can weaken hormone release [11]. |
DAC can prolong both hormone rises and unwanted effects
Sermorelin leaves blood within minutes to a few hours. CJC-1295 DAC can remain active much longer.
DAC means the drug attaches to albumin, a protein blood already carries. The attachment keeps the drug working for roughly 5-8 days [4].
Growth hormone and the liver's growth protein can stay raised throughout those days. That gives unwanted effects more time to last as well.
Growth hormone can make the body hold salt and water. Growth hormone also makes insulin work less well at keeping blood sugar down, so those lasting hormone levels matter if your health already involves diabetes, swelling, or other blood-sugar trouble.
CJC-1295 no-DAC, also called Modified GRF, clears within hours [7]. Product names and research discussions sometimes confuse DAC and no-DAC.
Reports of days of action concern DAC, the longer-lasting form. A report without the form name cannot tell you which length of action to expect.
Pharmacy permission does not equal approval of each drug
Sermorelin's old approval covered children lacking growth hormone. A study at several clinics found faster growth in those children [11].
2008: the maker stopped selling the approved drug for business reasons. Ending sales wasn't a finding of failed treatment or harm.
The FDA's Category 1 rules now let pharmacies prepare prescriptions under conditions. The FDA doesn't plan to stop preparation that meets those conditions.
The policy is temporary, so the rules can change. Each pharmacy-made drug hasn't passed FDA approval tests for the illness being treated.
A medical opinion article favored leaving natural limits on hormone release active [10]. A trial comparing adult treatments hasn't settled that argument.
CJC-1295 raised growth hormone and the liver's growth protein in early studies [4][5]. Those findings never led to treatment approval.
October 2024: FDA pharmacy advisers examined CJC-1295 and safety concerns [1]. They opposed adding the drug to a list of ingredients for pharmacy-made prescriptions.
One concern was the immune system fighting the drug. The review didn't establish which symptoms you might have from that reaction.
CJC-1295 still lacks large trials of treatment over years. Sermorelin has more child-treatment evidence, but neither drug has proved healthy-aging benefits.
Claims about healthy aging need tests in healthy adults
Both drugs prompt release of growth hormone made by the body. Neither has proved lasting benefits for healthy adults' aging, muscle growth, or fat loss.
2008: a medical opinion article found too little evidence for treatment against aging [9]. Later trial findings haven't settled that concern.
An advertisement may point to faster child growth or better thinking with a related drug. Neither finding tells you whether these shots help an older person stay well, because the drug, reason for treatment, and people tested can all differ from your own situation.
The findings still matter to the people and drugs studied. Claims about healthy adults need trials that test those claims.